Compare PRDO & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRDO | KOD |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 1997 | 2018 |
| Metric | PRDO | KOD |
|---|---|---|
| Price | $32.26 | $38.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $42.00 | $35.43 |
| AVG Volume (30 Days) | 610.6K | ★ 826.1K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ 10.50 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $581,296,000.00 | N/A |
| Revenue This Year | $4.28 | N/A |
| Revenue Next Year | $2.89 | N/A |
| P/E Ratio | $37.87 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.66 | $3.72 |
| 52 Week High | $38.50 | $47.84 |
| Indicator | PRDO | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 58.86 |
| Support Level | $31.37 | $32.93 |
| Resistance Level | $32.79 | $46.72 |
| Average True Range (ATR) | 1.03 | 2.77 |
| MACD | -0.04 | 0.66 |
| Stochastic Oscillator | 23.51 | 92.72 |
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the its revenue comes from the Colorado Technical University segment.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.